Dr. Brooke Luck is an Interdisciplinary Scientist at the Administration for Strategic Preparedness and Response’s (ASPR) Biomedical Advanced Research and Development Authority (BARDA), who leads the Biopharmaceutical Manufacturing Preparedness-Consortium (BioMaP-Consortium). The BioMaP-Consortium is a partnering mechanism that leverages BARDA’s Other Transaction (OT) Agreement authority to fund drug development and manufacturing, supply chain industrial base expansion, and advanced manufacturing technology innovations. She holds a B.S. in Biochemistry and Chemistry, a M.S. in Biotechnology and Biodefense, and a Ph.D. in Foreign Policy and Global Health. Dr. Luck has dedicated 15 years working for the U.S. Government supporting and leading government programs spanning biosurveillance, assay development, biothreat detection, CBRN defense, and quality assurance. Prior to BARDA, she worked for the United States Navy, in the medical research field, and as an analytical chemist in the private sector.
Global vaccine and biologics supply chains remain vulnerable to geopolitical shocks, raw material shortages, and capacity bottlenecks. This presentation introduces ATI’s BioMaP Consortium—a pre-competitive, industry-government collaboration designed to strengthen U.S. biopharmaceutical manufacturing resilience, continuity, and surge capacity. Attendees will learn how shared infrastructure, coordinated investment, and cross-sector execution models can transform supply chains from reactive to resilient.